– Mabion has secured up to EUR 3.1 million in loan financing from the Japanese company CBC Co., Ltd. to support short-term liquidity and ensure operational continuity in the period preceding a planned capital increase

• This transaction represents the third external debt financing secured by the Company in recent months, following previous bridge loans from Twiti Investments (up to PLN 18 million) and ACRX Investments (up to PLN 6 million)
• The partnership with CBC Co., Ltd., a global entity, provides Mabion with opportunities for geographic expansion into Asian markets and enhances the Company’s credibility among international business partners

Mabion S.A., a European biologics-focused CDMO, has entered into a loan agreement for up to EUR 3.1 million with CBC Co., Ltd., a Tokyo-based company. The funds will strengthen the Company’s liquidity during a key period of transformation and the implementation of its strategic ambitions for 2025–2030.

The financing will be made available to Mabion in two equal tranches for a period of 3 years from the date of disbursement. The interest rate is initially set at 10.53% per annum and, following a General Meeting resolution enabling debt-to-equity conversion, will be adjusted to the National Bank of Poland (NBP) reference rate plus a margin of 2 percentage points. The agreement includes an option that provides for the possibility of converting all or part of the loan, together with accrued interest, into shares of the Company at any time at the Lender’s request. The share price for the conversion will be equal to the market price of Mabion shares as at the date of execution of the agreement, taking into account a 20% discount, or, in the event of a share issue by the Company, will be equal to the share price offered to other investors. The transaction is secured by a mortgage on the Company’s real estate and a registered pledge on key production equipment, including bioreactors and manufacturing lines.

“Obtaining financing from CBC Co., Ltd. strengthens our financial liquidity and provides additional flexibility in the implementation of Mabion’s strategic goals. We treat this transaction as an important step in building long-term cooperation with an international partner who has experience in the life science sector and supports the development of technological projects with global potential. This financing, alongside the previously secured funds from Twiti Investments and ACRX Investments, provides us with the necessary operational comfort during a period of intensive business development. We are currently focused on building a portfolio of higher value-added projects, such as ADCs and biosimilars, which, combined with a stable financial foundation, will allow us to accelerate our path to profitability and build long-term value for our shareholders” said Gregor Kawaletz, CEO of Mabion S.A.

The agreement with CBC Co., Ltd. is part of broader measures to ensure Mabion’s operational stability. Previously, in October 2025, Mabion secured a bridge loan of up to PLN 18 million from its major shareholder, Twiti Investments Ltd.. This was followed in February 2026 by an agreement with ACRX Investments Limited for up to PLN 6 million. Together, these bridge funds provide Mabion with the operational flexibility to continue negotiations for a target medium-term financing structure and to pursue advanced discussions with global partners for new CDMO contracts.

The investor, CBC Co., Ltd., is a privately owned company specializing in advanced technology and life science sectors, founded in 1925. CBC acts as both an experienced operator and a strategic investor, executing a long-term value creation strategy focused on advanced technology and life science. The company runs a diversified trading-and-operating platform spanning chemicals and materials, pharmaceuticals and healthcare-related areas, agrochemicals, electronic components and devices, optical equipment, and selected industrial segments.

CBC is supported by an extensive international sales and distribution network across North America, Europe and Asia, complemented by manufacturing capabilities and laboratory infrastructure in selected locations.